Management of Transfusion-Related Iron Overload in Patients With Myelodysplastic Syndromes
| العنوان: | Management of Transfusion-Related Iron Overload in Patients With Myelodysplastic Syndromes |
|---|---|
| المؤلفون: | Sara Tinsley, Petra Lindroos-Kolqvist, Louise Arnold, Sandra E. Kurtin, Jayshree Shah |
| المصدر: | Clinical Journal of Oncology Nursing. 16:37-46 |
| بيانات النشر: | Oncology Nursing Society (ONS), 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | medicine.medical_specialty, Iron Overload, Pyridones, Anemia, Iron, Siderophores, Deferoxamine, Iron Chelating Agents, Benzoates, Gastroenterology, chemistry.chemical_compound, Phlebotomy, Internal medicine, medicine, Humans, Deferiprone, General Environmental Science, Ineffective Hematopoiesis, business.industry, Myelodysplastic syndromes, Deferasirox, Transfusion Reaction, Triazoles, medicine.disease, Chelation Therapy, Clinical trial, chemistry, Myelodysplastic Syndromes, Immunology, General Earth and Planetary Sciences, Packed red blood cells, business, medicine.drug |
| الوصف: | Anemia is a common symptom for patients with myelodysplastic syndromes (MDS), a spectrum of hematopoietic malignancies characterized by ineffective hematopoiesis; 90% of these patients will become transfusion dependent (TD). Because of the closed nature of iron metabolism, the repeated input of packed red blood cells during transfusions inevitably leads to iron overload. Iron overload can cause iron-related toxicity as well as end-organ damage from iron deposition in tissues. Studies have shown that patients with MDS who are TD have shorter overall survival, shorter leukemia-free survival, and higher healthcare costs compared with patients who are not TD, suggesting that iron overload has a significant clinical and economic impact. Iron chelation therapy can bind and eliminate free iron from the body. Although studies in genetic anemias have shown improved clinical outcomes, clinical trials with patients with MDS are ongoing. Because iron chelation therapy can be toxic, the risks, benefits, and therapy-related costs must be weighed for each patient. |
| تدمد: | 1538-067X 1092-1095 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2072ea570e90702e52747ffa39a4d5Test https://doi.org/10.1188/12.cjon.s1.37-46Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3d2072ea570e90702e52747ffa39a4d5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1538067X 10921095 |
|---|